Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Copalia HCT

Copalia HCT 5 mg/160 mg/12.5 mg film-coated tablets Copalia HCT 10 mg/160 mg/12.5 mg film-coated tablets Copalia HCT 5 mg/160 mg/25 mg film-coated tablets Copalia HCT 10 mg/160 mg/25 mg film-coated tablets Copalia HCT 10 mg/320 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9

HOS-122660 · Präparat HOS-095555

Copalia Known interactions Effect of the interaction with other medicinal products HCT with the following individual agents component Valsartan Lithium Reversible increases in serum lithium concentrations and and toxicity have been reported during concomitant HCT administration of lithium with ACE inhibitors, angiotensin II receptor antagonists including valsartan or thiazides. Since renal clearance of lithium is reduced by thiazides, the risk of lithium toxicity may presumably be increased further with Copalia HCT. Therefore careful monitoring of serum lithium concentrations is recommended during concomitant use. Valsartan Potassium-sparing If a medicinal product that affects potassium levels is diuretics, potassium considered necessary in combination with valsartan, supplements, salt frequent monitoring of potassium plasma levels is advised. substitutes containing potassium and other substances that may increase potassium levels Amlodipine Grapefruit or grapefruit Administration of amlodipine with grapefruit or grapefruit juice juice is not recommended as bioavailability may be increased in some patients, resulting in increased blood pressure lowering effects.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): potassium (HOS-086929) lithium (HOS-085952)